Gross et al., *"Antitumor Activity of the Glutaminase Inhibitor CB-839 in TNBC"*
Supplementary Figure S6



Supplementary Figure S6: The basal glutamate to glutamine ratio and the fold change in glutamine and glutamate following CB-839 treatment is greater in TNBC cells than receptor-positive cell lines. A, basal ratio of intracellular glutamate to glutamine (levels measured by LC/MS/MS) across a panel of TNBC and receptor-positive breast cancer cell lines. The glutamate to glutamine ratio (mean and SEM of duplicate measurements) for each cell line is graphed on a log2 scale in descending order. B, the fold increase in intracellular glutamine (measured by LC/MS/MS) across a panel of TNBC and receptor-positive breast cancer cell lines following treatment with 1 μM CB-839 for 4 hours. The fold glutamine increase relative to DMSO control (mean and SEM of duplicate measurements) for each cell line is graphed on a log2 scale in descending order. C, the fold decrease in intracellular glutamate (measured by LC/MS/MS) across a panel of TNBC and receptor-positive breast cancer cell lines following treatment with 1 μM CB-839 for 4 hours. The fold glutamate decrease relative to DMSO control (mean and SEM of duplicate measurements) for each cell line is graphed on a log2 scale in descending order. The basal-like ER-/HER2+ cell lines JIMT-1 and HCC1954 are annotated with asterisks (*).